At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 2 enrolled
Drug / intervention
Belatacept +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Renal Allograft Tolerance Through Mixed Chimerism (Belatacept)
In Brief
A Phase 1 clinical trial evaluating Belatacept, ATG, and 4 other interventions for Kidney Failure, Chronic and Renal Insufficiency. Completed, enrolled 2 participants across 1 site.
Detailed Summary
This study will examine the safety and effectiveness of a combination kidney and bone marrow transplant from a haplo-identical related donor. An investigational medication and other treatments will be given prior to and after the transplant to help protect the transplanted kidney from being attacked by the body's immune system
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKidney Failure, Chronic, Renal Insufficiency
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 2014
Enrollment StartFeb 2015
Primary CompletionMar 2021
Study CompletionJul 2021
TodayJul 2026
First PostedDec 11, 2014
Enrollment StartFeb 1, 2015
Primary CompletionMar 1, 2021
Study CompletionJul 1, 2021
TodayJul 2, 2026
Enrollment to primary: 6.1 yearsPosted 11.6 years ago
Interventions
Belataceptdrug
A selective T-cell (lymphocyte) costimulation blocker
ATGdrug
A T-Cell Depleting Agent
Rituximabdrug
B-Cell Depleting Agent
Total Body Irradiationradiation
Thymic Irradiationradiation
Combined Bone Marrow/Kidney Transplantationprocedure